Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
Pulmonary alveolar proteinosis (PAP) is associated with defective macrophage clearance of surfactant. Here, the authors show that patients with PAP have altered cholesterol-to-phospholipid ratio in their surfactant, and that more importantly, statin therapy and reduction of cholesterol accumulation...
Guardado en:
Autores principales: | Cormac McCarthy, Elinor Lee, James P. Bridges, Anthony Sallese, Takuji Suzuki, Jason C. Woods, Brian J. Bartholmai, Tisha Wang, Claudia Chalk, Brenna C. Carey, Paritha Arumugam, Kenjiro Shima, Elizabeth J. Tarling, Bruce C. Trapnell |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8cc338509bd449f91fc403c8ee500b8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review
por: Ali Ataya, et al.
Publicado: (2021) -
Proteinosis alveolar pulmonar
por: Rioseco S.,Patricio
Publicado: (2019) -
Proteinosis alveolar pulmonar, caso clínico
por: PARAM S,TERESA, et al.
Publicado: (2007) -
Proteinosis alveolar pulmonar en un lactante
por: Latorre L,Juan J, et al.
Publicado: (1973) -
Update on Diagnosis and Treatment of Adult Pulmonary Alveolar Proteinosis
por: Iftikhar H, et al.
Publicado: (2021)